Dear Senior,

If you are experiencing forgetfulness or memory issues, we are offering free “Memory Screening”, which involves a simple test to help us determine if your memory problems may be something that needs to be addressed clinically.  If eligible, you will be invited to participate in one of our research studies.

Please, be aware that, even if you are eligible, your participation in any research study is completely voluntary. There will be no consequences to you what-so-ever if you choose not to participate, and your regular medical care will not be affected by that choice.

Clinical trials are vital in the advancement of better medicines to treat cognitive impairment (memory loss). Your participation may have a positive impact on this advancement and improve outcomes for those who may develop memory loss.

In order to determine your eligibility or to know more about these studies, please contact the research at 954-366-0277.

Please feel free to call and make an appointment today.

Respectfully yours,

The Physicians and the Infinity Clinical Research Team in Hollywood, Florida



4925 Sheridan Street, Suite 200, Hollywood, FL 33021 Phone: 954-366-0277 Fax: 954-620-3310  



Dr. Cutler
Barry Cutler, MD

Richard Singer, MD

Brian Steingo, MD

Dr. Ginsberg
Paul Ginsberg, MD
Dr. Padilla
Alvaro Padilla, MD
Dr. Schwartz
Harvey Schwartz, MD
Dr. Gittler
Steven B. Gittler, MD
Dr. Gotkin
Brian M. Gotkin, MD


infinityclinicalresearch Microsoft Word - MemScreenFlyer9.17.15.docx



<span style=”font-family: arial, helvetica, sans-serif;”><strong>The facts about participating in clinical research and our ongoing studies:</strong></span>

<span style=”font-family: arial, helvetica, sans-serif;”>First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.</span>

<span style=”font-family: arial, helvetica, sans-serif;”>Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.</span>

<strong><span style=”font-family: arial, helvetica, sans-serif;”>For more information, please call: 954-366-0277.</span></strong>


<span style=”font-family: arial, helvetica, sans-serif;”><strong>CURRENTLY ENROLLING STUDIES</strong></span>
<p style=”text-align: center;” align=”center”><span style=”color: #943634;”><b><span style=”text-decoration: underline;”>HOLLYWOOD NEUROLOGY</span></b></span></p>
<p style=”text-align: left;” align=”center”><b><strong>For more information, please call: 954-366-0277.</strong><span style=”text-decoration: underline;”>
<span style=”color: #943634;”>Merck – APECS:</span><b> <i>  Memory Loss</i></b><b><i>
</i></b>A two-year study with a new oral drug as a potential disease-modifying therapy in patients 50 to 85 years old who have been experiencing memory loss for a year.

<span style=”color: #943634;”>Merck – EPOCH:</span> <i> </i><b><i> <b><i>Alzheimer’s Disease</i></b></i></b><b><i>
</i></b>A two-year study to evaluate potential disease-modifying therapy (the same medicine as in APECS) in patients 55 to 85 years old with mild to moderate Alzheimer’s Disease.

<span style=”color: #800000;”>Merck – 012:</span><b><i>   <b><i>Alzheimer’s Disease</i></b></i></b><b><i>
</i></b>A 6-month study evaluating the effectiveness of a new oral medicine for those patients between 55 and 85 years old and already on a stable dose of Aricept for treating the symptoms of mild to moderate Alzheimer’s Disease.

<span style=”color: #943634;”>Roche – MARGUERITE ROAD:</span><b><span style=”color: #943634;”> </span><i>  </i></b><b><i>Alzheimer’s Disease
</i></b>A two-year study with a potential disease modifying treatment given by subcutaneous injection in patients 50 to 90 years old with mild Alzheimer’s Disease.

<span style=”color: #800000;”>Toyoma / Alzheimer’s Disease Cooperative Study (UCSD) – NOBLE:</span><i></i><b><i>
</i></b>A one-year study to evaluate the neuro-protective effects of a new oral medication in patients who are 55 to 85 years old with mild to moderate Alzheimer’s Disease and on Aricept for at least 6 months with a stable dose for at least 3 months.

<span style=”color: #943634;”>Allergan – 127:</span><i><span style=”color: #943634;”> </span></i><b><i>  </i></b><b><i>Post-Stroke Upper Limb Spasticity
</i></b><b><i> </i></b>Botox® Treatment in Adult Patients with Upper Limb Spasticity – A 16-week study evaluating Botox in patients 18 to 80 years old with upper limb spasticity involving the elbow and shoulder due to stroke.

<span style=”color: #943634;”>Guerbet – REMIND:</span><b><i>   </i></b><b><i>Brain Tumors
</i></b>A 6-week study evaluating adult patients with known or highly suspected brain tumors that have been detected by previous CT or MRI examination and who are scheduled to undergo a routine contrast-enhanced MRI.  The contrast agent in this study is already FDA approved!

<p align=”center”><span style=”color: #943634;”><b><span style=”text-decoration: underline;”>HOLLYWOOD PULMONARY</span></b></span></p>
<p style=”text-align: left;” align=”center”><b><em><strong>Lead Study Coordinator: Lucy Vargas
</strong></em>954-981-4491 / <span style=”text-decoration: underline;”><a href=””></a>
<b><span style=”color: #943634;”>Forest – ASCENT COPD:</span><i><span style=”color: #943634;”> </span>  </i></b><b><i>Moderate to Severe COPD with High Cardiovascular Risk
</i></b>A three-year post-marketing study to evaluate the effect of aclidinium bromide (Tudorza Pressair) on long-term cardiovascular safety and COPD attacks in patients 40 years old or older who are current or former smokers, with moderate to very severe COPD and a history of cardiovascular or cerebrovascular disease and/or significant cardiovascular risk.  This medicine is already FDA approved!

<b><span style=”color: #943634;”>Glaxo SmithKline – IMPACT:</span><i><span style=”color: #943634;”> </span>  Chronic Obstructive Pulmonary Disease</i></b><b><i>
</i></b>A one-year study comparing the efficacy, safety and tolerability of  the investigational fixed dose triple combination therapy fluticasone furoate / umeclidinium / vilanterol trifentate (FF / UMEC / VI) compared with one of the FDA approved fixed dose dual combinations of Breo Ellipta (fluticasone furoate / vilanternol), a medicine similar to Advair, and Anoro Ellipta (umeclidinium / vilanterol) a medicine similar to Spiriva plus a fast-acting broncho-dilator; all administered once-daily in the morning with a dry powder inhaler in patients 40 years old or older with chronic obstructive pulmonary disease who are current or former smokers of at least 10 years.

<p align=”center”><span style=”color: #943634;”><b><span style=”text-decoration: underline;”>PLANTATION CARDIOLOGY</span></b></span></p>
<em><strong>Study Coordinator: Becky Nembhard
</strong></em>954-306-8163 / <a href=””></a>

<span style=”color: #943634;”><strong>Sanofi – ODYSSEY:</strong> </span><strong><i>Recent Acute Coronary Syndrome with Obstructive Coronary Disease</i></strong><b>
</b>A five-year study comparing a novel new class of drug on the occurrence of cardiovascular events in patients at least 40 years old who have experienced an acute coronary syndrome (ACS) event (unstable angina or heart attack) and despite intensive lipid modifying or statin therapy, are not adequately controlled.

<span style=”color: #943634;”><strong>Population Health Research Institute – <em><span style=”color: #000000;”>PALM Registry: Patient Assessment of Lipid Management</span></em><i>
</i></strong></span>One day trial: Patient questionnaire regarding their treatment of cholesterol with single blood draw.

<p align=”center”><span style=”color: #943634;”><b><span style=”text-decoration: underline;”>SUNRISE NEUROLOGY</span></b></span></p>
<strong>Clinical Study Coordinators:</strong>
Michele Kroll Fistel, LPN, CCRC; Dalia Ramos, RMA, CCRP; Fanny Gully, CRC; Magdeli Ramos, CCRC

<span style=”color: #993300;”><strong>Acorda Therapeutics – <span style=”color: #000000;”>MILESTONE: Walk Deficit in Post-Ischemic Stroke</span></strong></span>
A 20- week long study to determine the effect of two dose strengths of a currently FDA approved Extended Release tablet, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.

<span style=”color: #993300;”><strong>Adamas Pharmaceuticals – <span style=”color: #000000;”>EASE LID: Parkinson’s Disease with Levodopa Induced Dyskinesias</span></strong></span>
A 25-week long study with optional long term extension study testing the Efficacy and Safety of a modified extended-release version of amantadine for the Treatment of Levodopa Induced Dyskinesia in Parkinson’s Disease Patients

<span style=”color: #993300;”><strong>AstraZeneca – <span style=”color: #000000;”>AMARANTH: Early Alzheimer’s Disease</span></strong></span>
A 24-month long study to evaluate a potential disease modifying therapy, oral formulation, in patients between 55 and 85 years old with early Alzheimer’s disease.

<span style=”color: #993300;”><strong>Biogen Idec – <span style=”color: #000000;”>ENHANCE: Multiple Sclerosis-Walking ability, balance, upper extremity function</span></strong> </span>
A 24-week long study to determine whether prolonged-release medication, taken twice daily, has a clinically meaningful effect on patient-reported walking ability, balance and upper extremity function.

<span style=”color: #993300;”><strong>Daiichi Sankyo: <span style=”color: #000000;”>Fibromyalgia</span></strong></span>
A 21-week long study with optional long-term, open label extension to test effectiveness of an investigational drug compared to an FDA approved drug on fibromyalgia pain.

<span style=”color: #993300;”><strong>Forum Pharmaceuticals: <span style=”color: #000000;”>Mild to Moderate Alzheimer’s disease</span></strong> </span>
A 26-week long study to test effectiveness of two doses of an investigational medication in patients 55-85 years of age, with Mild to Moderate Alzheimer’s disease currently or previously treated with an AChEI (donepezil, rivastigmine, or galantamine).

<span style=”color: #993300;”><strong>Lundbeck-STARBEAM: <span style=”color: #000000;”>Mild to Moderate Alzheimer’s disease</span></strong></span>
A 28-week long study with optional long term, open-label extension study in patients with mild-moderate Alzheimer’s disease treated with donepezil as adjunctive therapy for symptomatic treatment of patients with mild-moderate Alzheimer’s disease (AD).

<span style=”color: #993300;”><strong>Merck: <span style=”color: #000000;”>Mild to Moderate Alzheimer’s disease</span></strong></span>
A 29-33 week long study to evaluate the potential of an oral investigational medication on improving memory in mild to moderate Alzheimer’s patients, 55-85 years of age, currently taking donepezil.

<span style=”color: #993300;”><strong>Novartis – <span style=”color: #000000;”>ASSESS: Relapsing-Remitting MS</span></strong></span>
A one-year study to compare efficacy and safety of 2 doses of oral Fingoli mod (Gilenya) to Copaxone in adults at least 18 yea rs old with relapsing remitting multiple sclerosis.

<span style=”color: #993300;”><strong>Sun Pharma – SPASTICIT Y: <span style=”color: #000000;”>Spasticity Due to Ms</span></strong></span>
A 22-week study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to multiple sclerosis.

<span style=”color: #993300;”><strong>Sun Pharma – SPASTICITY OL: <span style=”color: #000000;”>Spasticity Due to MS</span></strong> </span>
A long-term safety study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to MS, who completed 26 weeks of treatment in the spasticity trial.

<span style=”color: #993300;”><strong>TransTech Pharma:</strong> </span>
An 18-month long study testing the efficacy and safety of an investigational medication on improving memory in patients with mild Alzheimer’s disease, age 50 and over, that are currently taking AChEI (donepezil, rivastigmine, or galantamine) or memantine.